Zur Kurzanzeige

2019-06-06Zeitschriftenartikel DOI: 10.25646/6299
Partnering for enhanced digital surveillance of influenza‐like disease and the effect of antivirals and vaccines (PEDSIDEA)
dc.contributor.authorRath, Barbara
dc.contributor.authorMaltezou, Helena C.
dc.contributor.authorPapaevangelou, Vassiliki
dc.contributor.authorPapagrigoriou‐Theodoridou, Maria‐Alexandra
dc.contributor.authorAlchikh, Maren
dc.contributor.authorMyles, Puja
dc.contributor.authorSchweiger, Brunhilde
dc.contributor.authorPEDSIDEA Network
dc.date.accessioned2019-09-24T11:56:28Z
dc.date.available2019-09-24T11:56:28Z
dc.date.issued2019-06-06none
dc.identifier.other10.1111/irv.12645
dc.identifier.urihttp://edoc.rki.de/176904/6313
dc.description.abstractBackground Standardised clinical outcome measures are urgently needed for the surveillance of influenza and influenza‐like illness (ILI) based on individual patient data (IPD). Objectives We report a multicentre prospective cohort using a predefined disease severity score in routine care. Patients/Methods The Vienna Vaccine Safety initiative (ViVI) Disease Severity Score (“ViVI Score”) was made available as an android‐based mobile application to three paediatric hospitals in Berlin and Athens between 2013 and 2016. Healthcare professionals assessed ILI patients at the point of care including severity, risk factors and use of antibiotics/antivirals/vaccines. RT‐PCR for influenza A/B viruses was performed at the Hellenic Pasteur Institute and the Robert Koch Institute. PCR testing was blinded to severity scoring and vice versa. Results A total of 1615 children aged 0‐5 years (54.4% males) were assessed at the three sites. The mean age was 1.7 years (SD 1.5; range 0‐5.9). The success rate (completion of the scoring without disruption to the ER workflow) was 100%. ViVI Disease Severity Scores ranged from 0 to 35 (mean 13.72). Disease severity in the Berlin Cohort was slightly higher (mean 15.26) compared to the Athens Cohorts (mean 10.86 and 11.13). The administration of antibiotics was most prevalent in the Berlin Cohort, with 41.2% on antibiotics (predominantly cefuroxime) as opposed to only 0.5% on neuraminidase inhibitors. Overall, Risk‐adjusted ViVI Scores were significantly linked to the prescription of both, antibiotics and antivirals. Conclusions The Risk‐adjusted ViVI Score enables a precision medicine approach to managing ILI in multicentre settings. Using mobile applications, severity data will be obtained in real time with important implications for the evaluation of antiviral/vaccine use.eng
dc.language.isoengnone
dc.publisherRobert Koch-Institut
dc.rights(CC BY 3.0 DE) Namensnennung 3.0 Deutschlandger
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/de/
dc.subjectchildreneng
dc.subjectdisease severityeng
dc.subjectILIeng
dc.subjectinfluenzaeng
dc.subjectmobile healtheng
dc.subjectstandardizationeng
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titlePartnering for enhanced digital surveillance of influenza‐like disease and the effect of antivirals and vaccines (PEDSIDEA)none
dc.typearticle
dc.identifier.urnurn:nbn:de:kobv:0257-176904/6313-9
dc.identifier.doihttp://dx.doi.org/10.25646/6299
dc.type.versionpublishedVersionnone
local.edoc.container-titleInfluenza and Other Respiratory Virusesnone
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttps://onlinelibrary.wiley.com/doi/full/10.1111/irv.12645none
local.edoc.container-publisher-nameWiley-Blackwell - STMnone
local.edoc.container-volume13none
local.edoc.container-issue4none
local.edoc.container-reportyear2019none
local.edoc.container-year2019none
local.edoc.container-firstpage309none
local.edoc.container-lastpage318none
local.edoc.rki-departmentInfektionskrankheitennone
dc.description.versionPeer Reviewednone

Zur Kurzanzeige